Pfizer, BioNTech Launch Phase 1 Study Of Combo COVID And Flu Vax

By Lia DeGroot / November 3, 2022 at 3:05 PM

Pfizer and BioNTech are the latest companies to begin studying a combination COVID-19-flu vaccine, BioNTech announced Thursday (Nov. 3) as public health officials warn of a potential “tripledemic” -- a combination of severe flu, respiratory syncytial virus (RSV) and continued COVID-19 cases -- this fall.

Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.

FEATURES

NEWSLETTERS

ABOUT US

Inside Health Policy is a subscription-fee-based daily digital news service from Inside Washington Publishers.

SITE LICENSES

Economical site license packages are available to fit any size organization, from a few people at one location to company-wide access. For more information on how you can get greater access to Inside Health Policy for your office, contact Online Customer Service at 703-416-8505 or healthpolicy@iwpnews.com.

STAY CONNECTED

Pfizer, BioNTech Launch Phase 1 Study Of Combo COVID And Flu Vax

Log in to access this content.

Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.